PARSIPPANY, N.J., Sept. 7 /PRNewswire/ — DSM Pharma Chemicals,
a business unit of DSM Pharmaceutical Products, today announced the
launch of InnoSyn™ route scouting services. In response to
the increasing interest of pharmaceutical customers to outsource
the development of robust low-cost manufacturing routes, DSM is
offering focused and flexible stand alone route scouting services.
DSM’s route scouting capabilities lead to significant cost
savings by the reduction of synthesis steps or redesign of
The InnoSyn™ route scouting team supports research and
development, and the implementation of economical and scalable
routes. Unique value creating solutions are provided by integrating
the full range of enabling DSM competencies such as biocatalysis,
homogeneous catalysis, organic synthesis and continuous chemistry
using for example micro reactors. These capabilities to rapidly
screen a wide variety of catalysts speed up feasibility studies for
chemocatalytic and biocatalytic steps.
Recent success stories have introduced new efficient enzymes,
such as pharmaPLE®, lyases, transaminases, dehydrogenases and
new, easily accessible homogeneous catalysts for asymmetric
hydrogenations, aromatic substitutions, and oxidations.
Furthermore, a safe and clean nitration reaction was implemented
under cGMP for manufacturing of an API based on DSM’s micro reactor
technology. InnoSyn™services are based in DSM’s Geleen,
The Netherlands R&D facilities and utilize DSM’s wide range of
technology and production sites across Europe.
Oliver May, Ph.D., Business Manager InnoSyn™ route
scouting services commented, “DSM is recognized as a reliable and
leading large scale cGMP manufacturer for registered intermediates
and active pharmaceutical ingredients. This remains our focus but
we also want to continuously serve changing customer needs whenever
DSM can provide real value. Due to the reduced focus and